Change in patient‐reported symptom scores (lower is favored) · people with dry eye
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks (lower is favored) · people with dry eye
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Necrotising enterocolitis · very preterm or very low birth weight infants
Slow showed no clear difference in necrotising enterocolitis before hospital discharge compared with faster rates of enteral feed advancement (moderate certainty).
1 finding from 1 review
Mortality before hospital discharge · very preterm or very low birth weight infants
Slow showed no clear difference in mortality before hospital discharge compared with faster rates of enteral feed advancement (moderate certainty).
1 finding from 1 review
Feed intolerance · very preterm or very low birth weight infants
Slow may leads to higher feed intolerance before hospital discharge compared with faster rates of enteral feed advancement (low certainty).
1 finding from 1 review
Invasive infection (before hospital discharge) · very preterm or very low birth weight infants
Slow showed no clear difference in invasive infection before hospital discharge compared with faster rates of enteral feed advancement (low certainty).
1 finding from 1 review
Serum low‐density lipoprotein (LDL, mmol/L) · adults with or without existing CVD
2 findings from 1 review
Mortality: lung cancer · healthy adults
Low‐dose computed tomography (LDCT) screening probably leads to lower lung cancer‐related mortality ‐ planned time points compared with no LDCT screening (moderate certainty).
1 finding from 1 review
All‐cause mortality ‐ planned time points · healthy adults
Low‐dose computed tomography (LDCT) screening probably leads to lower all‐cause mortality ‐ planned time points compared with no LDCT screening (moderate certainty).
1 finding from 1 review
Overdiagnosis Time point: ≥ 10 years from randomisation excluding CXR trials  · healthy adults
Low‐dose computed tomography (LDCT) screening showed no clear difference in overdiagnosis Time point: ≥ 10 years from randomisation excluding… compared with no LDCT screening (low certainty).
1 finding from 1 review
Number of invasive tests Time point: 3 years to 10 years from randomisation  · healthy adults
1 finding from 1 review
Any death postsurgery Time point: 6 years to 9 years from randomisation · healthy adults
Low‐dose computed tomography (LDCT) screening showed no clear difference in any death postsurgery Time point: 6 years to 9 years from… compared with no LDCT screening (moderate certainty).
1 finding from 1 review
Health‐related quality of life ‐ anxiety Time point: 10 months to 5 years from randomisation Measured by different scales · healthy adults
Low‐dose computed tomography (LDCT) screening showed no clear difference in health‐related quality of life ‐ anxiety Time point: 10 months to 5… compared with no LDCT screening (low certainty).
1 finding from 1 review
 · healthy adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in weight (kg) · overweight and obese participants without T2DM (weight‐reducing phase only)
2 findings from 1 review
Change in weight (kg) · overweight and obese participants with T2DM (weight‐reducing phase only)
2 findings from 1 review
Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase only)
It is very uncertain whether summary of findings table ‐ Low‐carbohydrate weight‐reducing diets changes weight loss of at least 5% at ≥ 12 months compared with balanced‐carbohydrate weight‐reducing diets (very low certainty).
1 finding from 1 review
Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase only)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in DBP (mmHg) at ≥ 12 months · overweight and obese participants with T2DM (weight‐reducing phase only)
1 finding from 1 review
HbA1c (glycated haemoglobin), change · overweight and obese participants with T2DM (weight‐reducing phase only)
1 finding from 1 review